Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life-changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a…More valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders.
Social Media Links
REPORT RATINGS
4.8 / 5.0 (66)
Oxford Biomedica reports have an aggregate usefulness score of 4.8 based on 66 reviews.